Imatinib mesilate. Treatment of chronic myeloid leukemia Brc-Abl tyrosine kinase inhibitor

Drugs of the Future

Volumn 26, Issue 6, 2001, Pages 545-552

  De Bree, F ^a   Sorbera, L A ^a   Fernandez R ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GGP 57148B; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL MODEL; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; NUDE MOUSE; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0034802192     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.06.627415     Document Type: Article

References (44)

1. Potent and selective inhibitors of the Abl-kinase: Phenylaminopyrimidine (PAP) derivatives
2. The biology of chronic myeloid leukemia
3. The BCR gene and Philadelphia chromosome-positive leukemogenesis
4. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
5. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
6. Chronic myelogenous leukemia: Update on biology and treatment
7. Chronic myeloid leukemia
8. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
9. Chronic myelogenous leukemia: A review
10. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
11. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
12. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
13. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
14. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
15. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
16. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
17. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis
18. Effect of the tyrosine kinase inhibitor STI571 on colony formation from CML and normal bone marrow cells and from leukemic and non-leukemic cell lines
19. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
20. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
21. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
22. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
23. 1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the abl inhibitor STI571
24. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone and prostate of nude mice
25. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
26. Effects of food on STI571 GLivec pharmacokinetics and bioavailability
27. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
28. STI-571 induces mixed chimerism in patients relapsing in blastic transformation after allogeneic stem cell transplantation for chronic myeloid leukemia
29. Effects of STI571 on bone marrow morphology in patients with CML: A longitudinal study of 49 patients
30. Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML)
31. A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias
32. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
33. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
34. STI571 administered to chronic myeloid leukemia (CML) patients inhibits cell proliferation, induces apoptosis and initially causes partial inhibition of BCR/ABL autophosphorylation
35. STI571 in the treatment of pediatric Philadelphia (Ph+) chromosome-positive leukemia: A children's oncology group phase 1 study (P-9973)
36. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
37. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117)
38. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study
39. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST)
40. Novartis launches Gleevec in U.S. for treatment of CML
41. Phase I trial of a specific Abl tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients
42. Phase I trial of a specific Abl tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients
43. Clinical pharmacokinetics and pharmacodynamics of STI571 in a phase 1 trial in chronic myelogenous leukemia (CML) patients